Drug intelligence / Profile preview

gMSC2

Development stage: Unknown
Lead developer: Two Cells
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intravenous

Overview

gMSC2 is an allogeneic mesenchymal stem cell (MSC) therapy developed by Two Cells for the treatment of cerebral infarction (stroke). The product utilizes GMP-grade MSCs to provide regenerative and neuroprotective effects in the brain following an ischemic event. Developed in collaboration with Hiroshima University, gMSC2 is designed to promote tissue repair and functional recovery. As of late 2024, the therapy has completed clinical research involving patients at Hiroshima University and is positioned in Phase 1 development.

Brand names: gMSC2gMSC-2gMSC 2
Other names: gMSC®2gMSC2 (脳梗塞細胞治療製品)

Beyond the preview

Go deeper on gMSC2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on gMSC2.

Explore the full profile